Clinical Trial: Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder

U.S., Nov. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07253207) titled 'Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder' on Nov. 18.

Brief Summary: The purpose of this study is using Duloxetine Hydrochloride Enteric Capsules as the positive control, to evaluate the efficacy and safety of Levomilnacipran Hydrochloride Extended-Release Capsules in patients with Major Depressive Disorder (MDD).

Study Start Date: Oct. 17, 2024

Study Type: INTERVENTIONAL

Condition: Major Depressive Disorder (MDD)

Intervention: DRUG: Levomilnacipran Hydrochloride Extended-Release Capsules

Treatment period:

1. Levomilnacipran Hydrochloride Extended-Relea...